Atrophic rhinitis vaccine composition triggers different serological profiles that do not correlate with protection.

@article{citeulike:2831632, abstract = {Atrophic rhinitis (AR) is a widespread and economically important disease of swine caused by Bordetella bronchiseptica and Pasteurella multocida. It can be controlled by vaccination. This study investigates the effect of altering the composition (adjuvants and/or addition of formalin-inactivated P. multocida toxin, fPMT) of conventional vaccines on the serological profile and on protection against AR in swine. A significantly higher B. bronchiseptica specific antibody titre was detected for vaccines with novel immunostimulants, the best being Montanide IMS 1313 (1:630 compared to 1:274 obtained with alum). The highest B. bronchiseptica antibody titre was demonstrated for a combination of B. bronchiseptica--fPMT, while PMT antibody titre was highest for monovalent fPMT (both adjuvanted with IMS 1313). The AR-specific antibodies were transmitted from dams to their offspring in similar titres and with the same hierarchy of effectiveness. After a B. bronchiseptica--P. multocida bacterial challenge, piglets from dams vaccinated with fPMT combined with B. bronchiseptica or B. bronchiseptica--P. multocida bacterins showed the lowest nasal lesions scores (4.5 and 3.2, respectively, out of a possible maximum score of 18). These combinations, both of which were adjuvanted with IMS 1313, gave the best protection against experimentally induced AR. Our results show that the adjuvant and the antigen composition of the vaccine strongly affect seroconversion, and that the AR-specific antibody titre does not necessarily correlate with the degree of protection.}, address = {Veterinary Medical Research Institute of the Hungarian Academy of Sciences, H-1581 Budapest, P.O. Box 18, Hungary. tibor@vmri.hu}, author = {Magyar, T. and Donk\'{o}, T. and Kov\'{a}cs, F. }, citeulike-article-id = {2831632}, comment = {received 26.05.2008 ---=note-separator=--- tibor@vmri.hu e-mail}, issn = {0236-6290}, journal = {Acta veterinaria Hungarica}, keywords = {atrophic, rhinitis}, month = {March}, number = {1}, pages = {27--40}, posted-at = {2008-05-25 21:46:36}, priority = {2}, title = {Atrophic rhinitis vaccine composition triggers different serological profiles that do not correlate with protection.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/18401954}, volume = {56}, year = {2008} }

TY - JOUR ID - citeulike:2831632 L3 - citeulike-article-id:2831632 TI - Atrophic rhinitis vaccine composition triggers different serological profiles that do not correlate with protection. JF - Acta veterinaria Hungarica VL - 56 IS - 1 SP - 27 EP - 40 AD - Veterinary Medical Research Institute of the Hungarian Academy of Sciences, H-1581 Budapest, P.O. Box 18, Hungary. tibor@vmri.hu SN - 0236-6290 N2 - Atrophic rhinitis (AR) is a widespread and economically important disease of swine caused by Bordetella bronchiseptica and Pasteurella multocida. It can be controlled by vaccination. This study investigates the effect of altering the composition (adjuvants and/or addition of formalin-inactivated P. multocida toxin, fPMT) of conventional vaccines on the serological profile and on protection against AR in swine. A significantly higher B. bronchiseptica specific antibody titre was detected for vaccines with novel immunostimulants, the best being Montanide IMS 1313 (1:630 compared to 1:274 obtained with alum). The highest B. bronchiseptica antibody titre was demonstrated for a combination of B. bronchiseptica--fPMT, while PMT antibody titre was highest for monovalent fPMT (both adjuvanted with IMS 1313). The AR-specific antibodies were transmitted from dams to their offspring in similar titres and with the same hierarchy of effectiveness. After a B. bronchiseptica--P. multocida bacterial challenge, piglets from dams vaccinated with fPMT combined with B. bronchiseptica or B. bronchiseptica--P. multocida bacterins showed the lowest nasal lesions scores (4.5 and 3.2, respectively, out of a possible maximum score of 18). These combinations, both of which were adjuvanted with IMS 1313, gave the best protection against experimentally induced AR. Our results show that the adjuvant and the antigen composition of the vaccine strongly affect seroconversion, and that the AR-specific antibody titre does not necessarily correlate with the degree of protection. KW - atrophic KW - rhinitis N1 - received 26.05.2008 N1 - tibor@vmri.hu e-mail AU - Magyar, T AU - Donkó, T AU - Kovács, F PY - 2008/03// UR - http://view.ncbi.nlm.nih.gov/pubmed/18401954 ER -